Wells Fargo Sticks to Their Buy Rating for Allergan (AGN)

By Ryan Adsit

Wells Fargo analyst David Maris maintained a Buy rating on Allergan (AGNResearch Report) today. The company’s shares closed last Monday at $157.87.

According to TipRanks.com, Maris has 0 stars on 0-5 star ranking scale with an average return of -11.5% and a 39.5% success rate. Maris covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Establishment Labs Holdings Inc, and Osmotica Pharmaceuticals Plc.

Currently, the analyst consensus on Allergan is a Moderate Buy with an average price target of $178.30.

See today’s analyst top recommended stocks >>

Based on Allergan’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $1.76 billion. In comparison, last year the company had a GAAP net loss of $473 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States.